Fernando Camacho
Overview
Explore the profile of Fernando Camacho including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tardio V, Yin P, Camacho F, Barakat M, Tsoukas M
Diabetes Obes Metab
. 2025 Feb;
PMID: 39927409
Aims: Oral treatment extended-release naltrexone/bupropion (NB) leads to significant weight loss, but its effect on body composition remains unclear. We investigated changes in body composition with dual-energy x-ray absorptiometry after...
2.
Arevalo C, Camacho F, Modrak J
Respir Med Case Rep
. 2025 Jan;
53():102153.
PMID: 39834687
An 89-year-old male with a medical history of non-ischemic cardiomyopathy was initially admitted with acute hypoxic respiratory failure attributed to heart failure exacerbation. Aside from progressive dyspnea, a non-pruritic, non-painful...
3.
Madec S, Irfan K, Velumani K, Baret F, David E, Daubige G, et al.
Sci Data
. 2023 May;
10(1):302.
PMID: 37208401
Applying deep learning to images of cropping systems provides new knowledge and insights in research and commercial applications. Semantic segmentation or pixel-wise classification, of RGB images acquired at the ground...
4.
Stakiw J, Kodad S, LeBlanc R, Sebag M, Hay A, Kukreti V, et al.
Clin Lymphoma Myeloma Leuk
. 2023 May;
23(7):484-490.
PMID: 37127473
Introduction/background: Daratumumab is an anti-CD38 monoclonal antibody initially approved as a single agent for the treatment of relapsed and refractory multiple myeloma. The infusion-related reactions (IRRs) commonly seen with intravenous...
5.
le Roux C, Fils-Aime N, Camacho F, Gould E, Barakat M
EClinicalMedicine
. 2022 Jun;
49:101436.
PMID: 35747175
Background: Extended-release (ER) naltrexone/bupropion (NB) was associated with greater weight loss than placebo in four randomized, 56-week trials. The association of NB with longer-term maintenance of weight loss remains unknown....
6.
Wharton S, Yin P, Burrows M, Gould E, Blavignac J, Christensen R, et al.
Int J Obes (Lond)
. 2021 Jun;
45(8):1687-1695.
PMID: 34083744
Background: Extended-release naltrexone/bupropion (NB) is indicated for chronic weight management. Incretin agents are recommended for patients with type 2 diabetes. This analysis looked at the add-on of NB to incretins...
7.
McIntyre R, Paron E, Burrows M, Blavignac J, Gould E, Camacho F, et al.
J Affect Disord
. 2021 May;
289:167-176.
PMID: 33989969
There is significant association between obesity and depression. Naltrexone/Bupropion (NB) is indicated for treatment of overweight and obesity (BMI ≥27 kg/m with a comorbidity or ≥30 kg/m). This post-hoc analysis...
8.
Ho G, Camacho F, Rogers A, Surg F, Cartotto R
J Burn Care Res
. 2021 Jan;
42(2):350.
PMID: 33492384
No abstract available.
9.
Moadel-Robblee A, Camacho F, Milner G, Kertzner A, Schlecht N
Complement Ther Med
. 2021 Jan;
57:102661.
PMID: 33418067
Peer navigators (PNs), including trained cancer survivor volunteers, can be an important resource to the cancer care team in reducing barriers to screening, treatment, and psychosocial care among underserved communities...
10.
Adibfar A, Camacho F, Rogers A, Cartotto R
Burns
. 2020 Dec;
47(1):58-66.
PMID: 33293152
Background: Vasopressors may be required during acute burn resuscitation to support mean arterial blood pressure, but their use is not well-described in the burn literature. The purpose of this study...